Masimo Corp MASI
We take great care to ensure that the data presented and summarized in this overview for MASIMO CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MASI
View all-
Black Rock Inc. New York, NY9.35MShares$1.61 Billion0.03% of portfolio
-
Politan Capital Management LP New York, NY4.71MShares$813 Million35.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.52MShares$780 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.53MShares$263 Million0.12% of portfolio
-
Rtw Investments, LP New York, NY1.46MShares$252 Million3.11% of portfolio
-
State Street Corp Boston, MA1.44MShares$248 Million0.01% of portfolio
-
Westfield Capital Management CO LP Boston, MA1.39MShares$241 Million0.88% of portfolio
-
Capital Research Global Investors Los Angeles, CA1.36MShares$235 Million0.04% of portfolio
-
Farallon Capital Management LLC San Francisco, CA1.26MShares$217 Million0.84% of portfolio
-
Ace Management Global Ltd. Sao Paolo, D5966KShares$167 Million38.42% of portfolio
Latest Institutional Activity in MASI
Top Purchases
Top Sells
About MASI
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.
Insider Transactions at MASI
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 13
2024
|
Tao Levy EVP, Bus Dev |
SELL
Payment of exercise price or tax liability
|
Direct |
14,398
-34.94%
|
$2,318,078
$161.68 P/Share
|
Nov 13
2024
|
Tao Levy EVP, Bus Dev |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+42.13%
|
-
|
Aug 08
2024
|
Joe E Kiani CEO and Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
231,748
+27.73%
|
$8,574,676
$37.84 P/Share
|
Jun 26
2024
|
Politan Capital Management LP |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,228
+0.03%
|
-
|
Jun 26
2024
|
Michelle Brennan Interim CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,228
+50.0%
|
-
|
Jun 26
2024
|
Craig B Reynolds Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,228
+6.18%
|
-
|
May 01
2024
|
Craig B Reynolds Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+36.49%
|
$230,000
$23.04 P/Share
|
Apr 26
2024
|
Craig B Reynolds Director |
SELL
Open market or private sale
|
Direct |
40,000
-84.38%
|
$5,440,000
$136.17 P/Share
|
Apr 26
2024
|
Craig B Reynolds Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+45.76%
|
$920,000
$23.04 P/Share
|
Feb 28
2024
|
Bilal Muhsin Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
745
-4.14%
|
$95,360
$128.7 P/Share
|
Feb 28
2024
|
Bilal Muhsin Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,010
+10.04%
|
-
|
Feb 28
2024
|
Joe E Kiani CEO and Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
3,929
-1.04%
|
$502,912
$128.7 P/Share
|
Feb 28
2024
|
Joe E Kiani CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
10,050
+2.6%
|
-
|
Feb 28
2024
|
Micah W Young EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
388
-3.55%
|
$49,664
$128.7 P/Share
|
Feb 28
2024
|
Micah W Young EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,004
+8.42%
|
-
|
Feb 28
2024
|
Tao Levy EVP, Bus Dev |
SELL
Payment of exercise price or tax liability
|
Direct |
401
-3.45%
|
$51,328
$128.7 P/Share
|
Feb 28
2024
|
Tao Levy EVP, Bus Dev |
BUY
Grant, award, or other acquisition
|
Direct |
1,004
+7.96%
|
-
|
Feb 28
2024
|
Thomas Samuel Mc Clenahan EVP, GEN COUNSEL & CORP SEC |
SELL
Payment of exercise price or tax liability
|
Direct |
394
-1.06%
|
$50,432
$128.7 P/Share
|
Feb 28
2024
|
Thomas Samuel Mc Clenahan EVP, GEN COUNSEL & CORP SEC |
BUY
Grant, award, or other acquisition
|
Direct |
1,004
+2.63%
|
-
|
May 26
2023
|
Adam Mikkelson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,435
+25.89%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 315K shares |
---|---|
Grant, award, or other acquisition | 15.1K shares |
Open market or private sale | 40K shares |
---|---|
Payment of exercise price or tax liability | 20.3K shares |